Identify, develop, and commercialize pharmaceutical products for unmet medical needs. Focus on therapeutic areas such as neuroscience and oncology. Now — the numbers.
Revenue is spread across several lines; no single product carries the company.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
At this burn rate the cash pile isn’t the pressing question — for now, time is on the company’s side.
This company is not turning a profit, so the market is pricing its sales instead: 3.6× for every dollar of annual revenue.
Against companies in its own sector, it looks cheaper than 73% of them.
Analysts' average target sits 18% above today's price.
We compared this company with its own sector across five subjects.
A score of 50 means class average.
Profit power and business quality lead the class.
A solid grade overall — yet the debt outweighs the cash. The strength here comes from earnings power.
Clearly above the class average — a step short of the very top.
Clearly below the class average.
Clearly above the class average — a step short of the very top.
Growth: Sales growth trails the sector average.
The stock trades near its peak today. For long-term holders the ride has paid off so far — though past performance guarantees nothing about the future.
The company sells $4.3B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $356.1M against $4.3B in annual sales.
The growth engine is running at low revs right now. Report-card grade: 28/100.
On our five-subject report card, JAZZ sits behind the class. A low grade doesn’t mean “doomed” — it means “big claim, small proof.”
The takeaway: JAZZ has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.
The total grade weighs these five subjects against the sector — it isn’t a simple average of the five.